Latest news with #OrdinaryGeneralMeeting
Business Wire
23-05-2025
- Business
- Business Wire
in View of the Potential Sale of the PlanetArt Division
PARIS--(BUSINESS WIRE)--Regulatory News: Claranova (Euronext Paris: FR0013426004 - CLA) announces that discussions with General Atlantic Credit's Atlantic Park fund and PlanetArt's Management Team regarding the potential sale of its PlanetArt division, announced on March 3, 2025 1, are advancing while the terms and conditions under which the sale would take place are not yet final. As announced, Claranova's objective remains to close this transaction before the end of June. In order to achieve this, and in view of the legal deadlines, the Board of Directors has decided to call an Ordinary General Meeting for the purpose, in particular, of approving the said sale. Therefore, Claranova informs its shareholders that its Ordinary General Meeting will be held on Friday, June 27, 2025, at 11:00 a.m. CET at the Business Center Tour Egée, 9-11 allée de l'Arche, 92400 Courbevoie. The preliminary convening notice, including the agenda and the draft resolutions to be submitted to the General Meeting, is published today in the Bulletin des Annonces Légales Obligatoires (BALO) and also on the Company's website in the Investors/Shareholder's Meeting section. Details of how to participate and vote at this Meeting are provided in the notice. In compliance with legal and regulatory conditions, documents and information relating to this General Meeting will be made available to shareholders and may be consulted on the Company's website as from June 6, 2025. The voting platform (VOTACCESS) for this General Meeting will be open as from June 11, 2025, and the possibility to vote via Internet will close on June 26, 2025, at 3:00 p.m. CET. Shareholders are informed that a convening notice will be published in the BALO at least fifteen days before the date of the Ordinary General Meeting, specifying any changes to the agenda and any amendments resulting from requests for the inclusion of draft resolutions. In the meantime, Claranova will keep its shareholders and the public informed of any developments in the discussions regarding this transaction. Financial calendar: July 31, 2025: FY 2024-2025 revenue October 29, 2025: FY 2024-2025 results About Claranova: Claranova is a global leader in e-commerce for personalized objects (photo prints, photo books, children's books, etc.) and software publishing (PDF, Photo and Security). As a truly international group, in 2024 it reported revenue of nearly a half a billion euros, with 95% of this amount originating from outside France. Through its products and solutions sold in over 160 countries, the Group's mission is to " Transform technological innovation into user-centric solutions". By leveraging its digital marketing expertise, AI and the analysis of data from over 100 million active customers worldwide, Claranova develops technological solutions, available online, on mobile devices and tablets, for a wide range of private and professional customers. Operating in high-potential markets, the Group will pursue a growth strategy focused on profitability and operational excellence, in line with its "One Claranova" strategic roadmap. Claranova is eligible for French 'PEA-PME' tax-advantaged savings accounts. For more information on Claranova Group: or All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
Yahoo
22-05-2025
- Business
- Yahoo
Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux
Daix, May 22, 2025 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l'Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company's share repurchase program approved by the Ordinary General Meeting of May 22, 2025, it being specified that the Company does not to date intend to pursue any objective other than to animate the market under a liquidity agreement which has been in place since the listing on Euronext. Securities concerned: shares issued by Inventiva SA. Maximum proportion of capital that may be purchased by the Company: 10%. Maximum number of its own shares that may be acquired by the Company, based on the number of shares making up the share capital as of May 19, 2025: 13 915 127; however, taking into account the 45 454 shares held in treasury, only 13 869 673 treasury shares are available to be acquired. Allocation of treasury shares as of May 19, 2025: the 45 454 treasury shares held as of May 19, 2025 are allocated for the purpose of ensuring the liquidity of or making the market in Inventiva's shares through the intermediary of an investment services provider acting independently within the framework of a market making agreement that complies with a code of conduct recognized by the Autorité des marchés financiers. Maximum price per share: 40 euros. Objectives: The objectives of the share repurchase program pursuant to the 22nd resolution of the Ordinary General Meeting of May 22, 2025 are as follows: to purchase or sell shares under a liquidity agreement entered into with an investment services provider, in accordance with the conditions set by the market authorities; to implement and perform obligations related to stock option programs or other share allocations to employees and corporate officers of the Company and, in particular, to allocate shares to employees and corporate officers of the Company in connection with (i) profit-sharing, or (ii) any share purchase, stock option or free share allocation plan under the conditions provided for by law, in particular by Articles L.3331- 1 seq. of the French Labor Code (including any sale of shares referred to in Article L.3332-24 of the French Labor Code), and to carry out any hedging transactions relating to such transactions; to deliver ordinary shares upon the exercise of rights attached to securities carrying rights to shares of the Company by redemption, conversion, exchange, presentation of a warrant or any other means; to reduce the Company's capital by cancelling all or some of the shares acquired; and more generally, to carry out any transaction that may be authorized by law or any market practice that may be admitted by the market authorities, it being specified that, in such a case, the Company would inform its shareholders by means of a press release. Duration of the program: 18 months from the Ordinary General Meeting of May 22, 2025. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts Inventiva Pascaline ClercEVP, Strategy and Corporate Affairs media@ +1 202 499 8937 Brunswick GroupTristan Roquet Montegon /Aude Lepreux /Julia CailleteauMedia relationsinventiva@ +33 1 53 96 83 83 ICR HealthcarePatricia L. BankInvestor +1 415 513 1284 Important Notice This press release contains certain 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva's cash resources, forecasts and estimates with respect to Inventiva's NATiV3 Phase 3 clinical trial of lanifibranor in MASH , including duration, timing and costs, and the results and timing thereof and regulatory matters with respect thereto, clinical trial data releases and publications, the potential therapeutic benefits of lanifibranor, and future activities, expectations, plans, growth and prospects of Inventiva, and the absence of material adverse events. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, 'believes', 'anticipates', 'expects', 'intends', 'plans', 'seeks', 'estimates', 'may', 'will', 'would', 'could', 'might', 'should', 'designed', 'hopefully', 'target', 'potential', 'opportunity', 'possible', 'aim', and 'continue' and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates due to a number of factors, including that the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva's ability to obtain financing and to enter into potential transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of its lanifibranor, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require additional holds and/or additional amendments to Inventiva's clinical trials, Inventiva's expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva's ability to identify additional products or product candidates with significant commercial potential, Inventiva's expectations with respect to its pipeline prioritization plan and related workforce reduction, including whether the plan will be implemented and the timing, potential benefits, expenses and consequences relating thereto, Inventiva's ability to execute on its commercialization, marketing and manufacturing capabilities and strategy, Inventiva's ability to successfully cooperate with existing partners or enter into new partnerships, and to fulfill its obligations under any agreements entered into in connection with such partnerships, the benefits of its existing and future partnerships on the clinical development, regulatory approvals and, if approved, commercialization of its product candidates, and the achievement of milestones thereunder and the timing thereof, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners' control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's business, and pre-clinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by changes in laws and regulations, unfavorable conditions in its industry, geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, the conflict in the Middle East and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers, international trade relations, political turmoil, and natural catastrophes, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2024 filed with the Autorité des Marchés Financiers on April 15, 2025 and the Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission (the 'SEC') on April 15, 2025 for other risks and uncertainties affecting Inventiva, including those described under the caption 'Risk Factors', and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. Attachment Inventiva - PR - Liquidity agreement Shareholders Meeting - EN - 05 22 2025
Yahoo
16-05-2025
- Business
- Yahoo
Information regarding the results of the vote on the resolutions presented (and all adopted) at the Annual General Meeting on May 15, 2025
Information regarding the results of the vote on the resolutions presented (and all adopted) at the Annual General Meeting on May 15, 2025 Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, held its Annual General Meeting on May 15, 2025, in Paris. A poll was held on each of the resolutions proposed. The results of the polls are set out below. Number of shareholders present, represented or voting by mail at the Ordinary General Meeting (OGM): 867 Number of shareholders present, represented or voting by mail at the Extraordinary General Meeting (EGM): 867 Number of voting rights exercisable as of May 15, 2025: 220,371,887 Total votes represented in the vote on the resolutions submitted to OGM: 202,370,496 Total votes represented in the vote on the resolutions submitted to EGM: 202,370,496 Results of the polls on the resolutions proposed under the jurisdiction of the Annual General Meeting: Ordinary resolutions Votes for Votes against Abstention Status Votes % Votes % Votes 1 Approval of the statutory financial statements for the year ended December 31, 2024 202,353,232 99.99% 4,984 0.01% 12,280 Agreed 2 Approval of the consolidated financial statements for the year ended December 31, 2024 202,352,506 99.99% 5,408 0.01% 12,582 Agreed 3 Allocation of net income for the year ended December 31, 2024 202,345,581 99.99% 11,409 0.01% 13,506 Agreed 4 Renewal of the term of office as director of Sarah Caulliez 191,539,101 95.46% 9,114,170 4.54% 1,717,225 Agreed 5 Appointment of a new director (Mr. Alexis Grolin) 191,963,604 95.67% 8,686,713 4.33% 1,720,179 Agreed 6 Appointment of a new director (Mr. Bertrand Cousin) 191,901,337 95.64% 8,749,796 4.36% 1,719,363 Agreed 7 Approval of the components of the compensation due or awarded to the President of the Board of Directors, Laurence Mulliez, for the 2024 financial year 185,896,774 92.19% 15,755,370 7.81% 718,352 Agreed 8 Approval of the compensation due or awarded to the Chief Executive Officer, Sébastien Clerc, for the 2024 financial year 188,753,931 94.39% 11,224,651 5.61% 2,391,914 Agreed 9 Vote on information relating to the 2024 compensation of the corporate officers (excluding executive corporate officers) set out in Article L22-10-9 of the French Commercial Code 186,355,873 93.99% 11,922,637 6.01% 4,091,986 Agreed 10 Approval of the 2025 compensation policy for corporate officers 200,220,113 99.91% 182,997 0.09% 1,967,386 Agreed 11 Approval of the 2025 compensation policy for the President of the Board of Directors 185,898,806 92.19% 15,748,751 7.81% 722,939 Agreed 12 Approval of the 2025 compensation policy for the Chief Executive Officer 191,759,291 95.68% 8,649,597 4.32% 1,961,608 Agreed 13 Determination of the overall compensation allocated to the members of the Board of Directors 200,218,372 99.91% 188,933 0.09% 1,963,191 Agreed 14 Authorization for the Board of Directors to purchase the Company's own shares 196,335,323 97.02% 6,028,019 2.98% 7,154 Agreed 15 Authorization to be granted to the Board of Directors to reduce the share capital by cancelling treasury shares 199,024,882 98.35% 3,337,323 1.65% 8,291 Agreed 16 Delegation of authority to the Board of Directors for the purpose of increasing the share capital without preferential subscription rights for a category of persons within the framework of implementing an equity or bond financing facility 183,223,915 90.54% 19,133,912 9.46% 12,669 Agreed 17 Delegation of authority to the Board of Directors for the purpose of increasing the share capital without preferential subscription rights for banks or financial institutions with the aim of promoting sustainable development in economic, social and/or environmental matters 183,221,130 90.54% 19,137,207 9.46% 12,159 Agreed 18 Delegation of authority to increase for the purpose of increasing the share capital, without preferential subscription for investors active in the field of energy, in particular renewable energies, and in the promotion of sustainable development in economic, social and/or environmental matters 183,222,922 90.54% 19,134,728 9.46% 12,846 Agreed 19 Delegation of authority to the Board of Directors to increase the share capital, with preferential subscription rights of the shareholders. 186,204,973 92.02% 16,158,574 7.98% 6,949 Agreed 20 Delegation of authority to the Board of Directors to increase share capital, with cancellation of shareholders' preferential subscription rights and public offering(s) (other than the offerings referred to in paragraph 1° of Article L. 411-2 of the French Monetary and Financial Code) 183,220,522 90.54% 19,138,867 9.46% 11,107 Agreed 21 Delegation of authority to the Board of Directors to increase share capital, with cancellation of shareholders' preferential subscription rights, in connection with offers referred to in paragraph 1° of Article L. 411-2 of the French Monetary and Financial Code. 182,792,794 90.52% 19,139,834 9.48% 437,868 Agreed 22 Delegation of authority to the Board of Directors to increase the number of securities to be issued in the event of a capital increase with or without preferential subscription rights 186,035,378 92.71% 14,627,440 7.29% 1,707,678 Agreed 23 Delegation of authority to issue ordinary shares and/or securities giving access to the Company's capital, in the event of a public offer with an exchange component initiated by the Company 183,599,179 90.73% 18,757,335 9.27% 13,982 Agreed 24 delegation of powers to increase the share capital to remunerate contributions in kind of equity securities or securities giving access to the capital of third-party companies outside a public exchange offer 185,946,332 91.89% 16,408,668 8.11% 15,496 Agreed 25 Setting the overall limits on the number of issues carried out by virtue of the above-mentioned delegations of authority 199,173,808 98.43% 3,181,897 1.57% 14,791 Agreed 26 Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital by issuing shares and securities convertible to capital of the Company without preferential subscription rights for shareholders for the benefit of the employees who are members of the Group savings plan 202,309,113 99.98% 49,625 0.02% 11,758 Agreed 27 amendment of Article 12 of the Articles of Association to conform with the new applicable legal provisions 202,346,226 99.99% 12,445 0.01% 11,825 Agreed 28 amendment of Article 23 of the Articles of Association 'Loss of half the share capital' to confirm with the new provisions of Article L. 225-248 of the French Commercial Code 202,335,661 99.99% 14,195 0.01% 20,640 Agreed Next on the agenda: Q2 2025 revenues, on July 23, 2025 (after market close) About Voltalia ( Voltalia is an international player in renewable energies. The Group produces and sells electricity from its wind, solar, hydro, biomass and storage facilities. It has 3.3 GW of capacity in operation and under construction, and a portfolio of projects under development with a total capacity of 17.4 GW. Voltalia is also a service provider, supporting its renewable energy customers at every stage of their projects, from design to operation and maintenance. A pioneer in the business market, Voltalia offers a comprehensive range of services to businesses, from the supply of green electricity to energy efficiency services and the local production of its own electricity. With more than 2,000 employees in 20 countries on 3 continents, Voltalia has the capacity to act globally on behalf of its customers. Voltalia is listed on the Euronext regulated market in Paris (FR0011995588 - VLTSA) and is included in the Enternext Tech 40 and CAC Mid&Small indices. The company is also included, amongst others, in the MSCI ESG ratings and the Sustainalytics ratings. VoltaliaEmail: invest@ +33 (0)1 81 70 37 00 Press Relations - Jennifer +33 (0)1 56 88 11 19 Attachment Information regarding the results of the vote on the resolutions presented (and all adopted) at the Annual General Meeting on May 15, 2025Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
CONVENING NOTICE TO THE ORDINARY GENERAL MEETING 2025 OF IBA SA
– WEDNESDAY, JUNE 11, 2025, AT 10:00 A.M. –Dear Shareholder, We have the honor of convening you to the Ordinary General Meeting (the "OGM") of IBA to be held on Wednesday June 11, 2025 at 10:00 A.M., to deliberate on the attached agenda. The OGM will be held in person at the Company's headquarters. There will also be an online webcast, accessible upon prior registration, but it will not be possible to vote online. This is a simple webcast. Shareholders are strongly encouraged to vote in advance of the OGM, within the legal deadlines, by proxy or via the remote voting form (both of which are provided herewith), in order to facilitate the counting of votes. Alternatively, shareholders are offered the possibility of voting via the platform (or, in the case of dematerialized shares, with the intervention of a financial intermediary acting on the instructions of the shareholder - via managed by ABN AMRO acting as agent of the Company. You will find all the formalities applicable for attending the OGM, together with the relevant forms, in attachment to this convening notice, as well as on our website ( on the Investor relations > Legal information > Shareholders' meetings page. If you have any questions concerning this convening notice, please send an e-mail to shareholderrelations@ sincerely. ________________________________ Saint-Denis SA President of the Board of Directors (Permanent representative: Mr P. Mottet) Attachments IBA - AGO 11.06.2025 - Convocations - ENGLISH VERSION IBA - AGO 11.06.2025 - Formulaire vote par correspondance IBA - AGO 11.06.2025 - Procuration IBA - AGO 11.06.2025 - Remuneration policy IBA - AGO 11.06.2025 - Results FY 2024 - ENGLISH IBA_Annual-Report-2024_ENError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
08-04-2025
- Business
- Zawya
Bank Muscat approves sukuk and bonds issuance, cash dividend for shareholders
Muscat – Bank Muscat held its Annual Ordinary General Meeting (AGM) and Extraordinary General Meeting (EGM) of shareholders on March 26, 2025, via the electronic platform of the Muscat Clearing and Depository website. Both meetings were chaired by Sheikh Khalid bin Mustahail al Mashani, Chairman of the Bank's Board of Directors. During the meetings, shareholders elected the Board of Directors for a three-year term (2025–2028). At the EGM, shareholders approved the renewal of the Meethaq Sukuk Programme and the issuance of sukuk amounting to RO500mn (or its equivalent in US dollars) in various tranches in both domestic and international markets, either through public subscription or private placement. Approval was also granted for the issuance of senior unsecured bonds in the local market under a Medium-Term Programme (MTP). Under the proposed MTP, the bank will issue senior unsecured bonds denominated in either Omani rials or US dollars in the local market, via private placement or public offering, in accordance with applicable laws and regulations in Oman. During the AGM, shareholders approved the distribution of a cash dividend of 16.5bz per share for the financial year 2024. Following the AGM, the Board of Directors convened a meeting in which Sheikh Khalid bin Mustahail al Mashani was reappointed as Chairman, and Sheikh Ahmed bin Hamed bin Hilal al Sadi was appointed Deputy Chairman. Speaking on the occasion, Mashani expressed his appreciation to shareholders, customers, and partners for their continued support and confidence in the Board of Directors and the bank's strong performance in delivering sustainable banking solutions aligned with evolving customer needs. He said, 'To further consolidate its leadership position in the sultanate's banking sector, Bank Muscat remains committed to investing in cutting-edge technologies and enhancing operational efficiency to deliver greater value to our customers. At the same time, we focus on competitiveness and the adoption of best practices and innovative products to serve a diverse customer base, ensuring we remain at the forefront of delivering high-quality banking services.' Bank Muscat reported a net profit of RO225.58mn for the year ended December 31, 2024, compared to RO212.45mn in the previous year, reflecting a year-on-year growth of 6.2%. © Apex Press and Publishing Provided by SyndiGate Media Inc. (
